Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/30243
Title: | Dual antiplatelet therapy after percutaneous left atrial appendage occlusion: single center experience with the Amplatzer Cardiac plug | Authors: | BERTRAND, Philippe Habran, Melanie Kenis, Karlijn Lecomte, Julie Moonen, Linde STROOBANTS, Didier BENIT, Edouard |
Issue Date: | 2019 | Publisher: | TAYLOR & FRANCIS LTD | Source: | ACTA CARDIOLOGICA, 74(1), p. 74-81 | Abstract: | Background: Percutaneous left atrial appendage occlusion (LAAO) is an alternative to anticoagulation in atrial fibrillation patients at high bleeding risk. Dual antiplatelet therapy (DAPT) is generally recommended in the months following the procedure to prevent thrombotic complications. The aim of this study was to evaluate the safety and efficacy of DAPT after LAAO in a single-centre population of high bleeding risk patients. Methods: All patients who received DAPT after LAAO using the Amplatzer Cardiac Plug at Jessa Hospital (Hasselt, BE) between February 2011 and October 2016 were included. Patient characteristics, procedural outcome and clinical events (bleeding, stroke and adverse events) were prospectively followed. Changes in antithrombotic and/or anticoagulant regimens were assessed. Results: Thirty-nine patients (77 +/- 7 years, 51% male, CHA(2)DS(2)-VASc 5(3-6), Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) 3(3-4)) were included. An initial strategy of one month DAPT (n = 2) was changed to six months DAPT (n = 37) after one thrombotic complication (device thrombosis) at 4.5 months. Post-procedural DAPT duration was 6.1 +/- 3.7 months, after which aspirin mono-therapy (62%), no antiplatelet/anticoagulant therapy (15%) or a tailored antithrombotic regimen was maintained. At mean follow-up of 21 +/- 13 months, seven patients had died (18%), no strokes had occurred (0%) and nine bleedings of which four were major (10%). All major bleedings occurred within the first six months after the procedure during DAPT. Conclusion: Antithrombotic therapy after percutaneous LAAO is needed to prevent thrombotic complications, yet these impose bleeding complications in this high-risk population. Further efforts are needed to define the optimal duration of DAPT, aimed at reducing bleeding complications while maintaining a low thrombosis rate. | Notes: | [Bertrand, Philippe B.; Stroobants, Didier; Benit, Edouard] Jessa Ziekenhuis, Heart Ctr Hasselt, Stadsomvaart 11, B-3500 Hasselt, Belgium. [Bertrand, Philippe B.; Habran, Melanie; Kenis, Karlijn; Lecomte, Julie; Moonen, Linde] Hasselt Univ, Fac Med & Life Sci, Diepenbeek, Belgium. | Keywords: | Left atrial appendage occlusion;bleeding;thrombosis and stroke;dual antiplatelet therapy;Amplatzer Cardiac Plug | Document URI: | http://hdl.handle.net/1942/30243 | ISSN: | 0001-5385 | e-ISSN: | 1784-973X | DOI: | 10.1080/00015385.2018.1455946 | ISI #: | 000459619200011 | Rights: | 2020 Informa UK Limited | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bertrand2018.pdf Restricted Access | Published version | 982.87 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
1
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
4
checked on May 16, 2024
Page view(s)
28
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.